2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12798E
    (R)-AR-13503 2377238-62-3 98.20%
    (R)-AR-13503 ((R)-AR-13324 M1 metabolite) is the the (R)-enantiomer of AR-13503 (HY-12798C). AR-13503 is the hydrolytic metabolite of AR-13324 mesylate. AR-13324 is a ROCK kinase and PKC inhibitor with anti-angiogenic and retinal health-improving effects, showing potential for use in retinal disease research.
    (R)-AR-13503
  • HY-128009
    ML161 analog 1 423740-83-4 99.62%
    ML161 analog 1 (compound 38) is an analog of ML161 (HY-13965). ML161 analog 1 is a selective allosteric inhibitor of PAR1 with an IC50 of 1.68 μM.
    ML161 analog 1
  • HY-128045
    Fenoxazoline 4846-91-7 98%
    Fenoxazoline is a decongestant and a vasoconstrictor.
    Fenoxazoline
  • HY-128060
    PDE5-IN-42 936449-28-4 98%
    PDE5-IN-42 (Compound 42) is a potent and orally active PDE5 inhibitor with an IC50 of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11.
    PDE5-IN-42
  • HY-128126
    B-TPMF 477865-65-9 98%
    B-TPMF is a selective inhibitor of the KCa2.1 channel, with an IC50 of 30 nM, and it has a competitive functional interaction with CM-TPMF.
    B-TPMF
  • HY-128345
    UDM-001651 1477497-01-0 98%
    UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP).
    UDM-001651
  • HY-128503
    TEI-2306 114627-30-4 98%
    TEI-2306 is a precursor of glutathione biosynthesis. TEI-2306 possesses a unique anti-HIV-1 activity in both chronically and acutely infected cells, and even for free viruses. TEI-2306 can be used for the study of myocardial ischaemia.
    TEI-2306
  • HY-128511
    Piridoxilate 24340-35-0 98%
    Piridoxilate (Piridoxylate), a glyoxylate derivative, is an anti-anoxic agent. Piridoxilate can be used in research on vascular diseases and coronary occlusion.
    Piridoxilate
  • HY-128543
    Zidapamide 75820-08-5 98%
    Zidapamide (Compound 4a) is an isomer of indapamide (HY-B0259). Zidapamide has diuretic and natriuretic activities. Zidapamide is used in the study of hypertension.
    Zidapamide
  • HY-128546
    Flupranone 21686-10-2 98%
    Flupranone is a pyrazole derivatives with antiinflammatory and antihypertensive properties.
    Flupranone
  • HY-128547
    Cetiedil citrate 16286-69-4 98%
    Cetiedil citrate is a vasodilator and antihemolytic agent. Cetiedil citrate exerts anti-sickle cell anemia effects by blocking Ca2+-activated K+ channels (Gardos/KCa3.1). Cetiedil citrate is a muscarinic receptor antagonist that inhibits calcium-dependent release of acetylcholine (ACh) from mediated reconstituted proteoliposomes, with a Ki value of 5 μM. Cetiedil citrate possesses analgesic, spasmolytic and local anesthetic activities. Cetiedil citrate can be used in research related to ischemic leg pain caused by vascular diseases and sickle cell disease.
    Cetiedil citrate
  • HY-128551
    Droprenilamine 57653-27-7 98%
    Droprenilamine is a coronary vasodilator.
    Droprenilamine
  • HY-128561
    AM12 2387510-84-9 98%
    AM12 inhibits Lanthanide-evoked TRPC5 activity with an IC50 of 0.28 μM.
    AM12
  • HY-12879G
    IWP-4 (GMP) 686772-17-8 98%
    IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure.
    IWP-4 (GMP)
  • HY-129088
    HUP30 312747-21-0 99.68%
    HUP30 is a vasodilating agent. HUP30 stimulates soluble guanylyl cyclase, activate K+ channels, and blocks extracellular Ca2+ influx.
    HUP30
  • HY-129199
    U-51605 64192-56-9 98%
    U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3).
    U-51605
  • HY-129210
    KMUP-4 864873-81-4 98%
    KMUP-4, as a xanthine derivative with cGMP-enhancing activity, induces aortic relaxation through endothelium-dependent and independent mechanisms. KMUP-4 increases cytoplasmic cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) levels by inhibiting phosphodiesterases (PDEs) and activating K+ channels. KMUP-4 can be used in the study of cardiovascular diseases.
    KMUP-4
  • HY-129213
    CL-242817 86709-48-0 98%
    CL-242817 is an orally available angiotensin converting enzyme (ACE) inhibitor. CL-242817 inhibits the conversion of angiotensin I to angiotensin II and has blood pressure lowering activity. CL-242817 can also improve Monocrotaline (HY-N0750) induced lung injury. CL-242817 can be used in the study of pulmonary fibrosis and hypertension-related diseases.
    CL-242817
  • HY-129230
    Triletide 62087-96-1 98%
    Triletide is a thromboxane A2 antagonist with good oral absorption activity. The biotransformation of Triletide mainly includes the formation of demethyl, deacetyl, demethyl-deacetyl and hydroxy derivatives. The distribution half-life of Triletide is about 1 hour, and the elimination half-life is about 5 hours.
    Triletide
  • HY-129244
    Levamlodipine gentisate 856256-16-1 98%
    Levamlodipine gentisate ((S)-Amlodipine gentisate) is a pharmacologically active amino ester with calcium channel blocker activity. Levamlodipine gentisate is used as an antihypertensive and antianginal compound. The enantiomeric purity of levamlodipine gentisate can be determined by a fast capillary electrophoresis method. The highest resolution of levamlodipine gentisate reached 9.8, indicating its potential application in compound analysis.
    Levamlodipine gentisate
Cat. No. Product Name / Synonyms Application Reactivity